San Diego-based Viking Therapeutics marked by itself as a significant competitor during the weight loss drug market place in February immediately after revealing promising data from a mid-stage trial of experimental drug VK2735, which advised it rivaled—and outperformed—Novo and Lilly drugs when presented as a weekly injection As well as in Mar